- Question
- Is first-line balloon cryoablation more effective than antiarrhythmic drugs at maintaining sinus rhythm in previously untreated patients with symptomatic paroxysmal atrial fibrillation?
- Design
- Randomized, open-label (unmasked) trial of 303 patients. All received an implantable cardiac monitor to detect atrial tachyarrhythmias. Follow-up was 12 months.
- Population
- Patients with symptomatic paroxysmal atrial fibrillation who had not previously received rhythm-control therapy.
- Intervention
- Catheter ablation with a cryothermy balloon (pulmonary vein isolation) as the initial rhythm-control strategy.
- Control
- Antiarrhythmic drug therapy according to local clinical practice and guideline-suggested management, as initial rhythm control.
- Primary outcome
- First documented recurrence of any atrial tachyarrhythmia (atrial fibrillation, atrial flutter, or atrial tachycardia) between days 91 and 365 after ablation or initiation of the antiarrhythmic drug.
- Results
- At 1 year, atrial tachyarrhythmia recurred in 66 of 154 patients (42.9%) in the ablation group and 101 of 149 (67.8%) in the drug group (HR 0.48; 95% CI 0.35 to 0.66; P<0.001). Symptomatic atrial tachyarrhythmia recurred in 11.0% with ablation and 26.2% with drugs (HR 0.39; 95% CI 0.22 to 0.68).
- Safety
- Serious adverse events occurred in 5 patients (3.2%) with ablation and 6 (4.0%) with antiarrhythmic drugs.
- Conclusion
- As initial treatment for symptomatic paroxysmal atrial fibrillation, cryoballoon ablation significantly reduced recurrences compared with antiarrhythmic drugs, as assessed by continuous rhythm monitoring.
- Why it matters
- It provided evidence supporting ablation as a first-line strategy, challenging the traditional approach of trying antiarrhythmic drugs first.
Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.
Generated on October 14, 2026